◈ Nootpedia
Compact view
Research pass: medium AAS · Oral SKIP-PERMANENT HIGH

Methyltestosterone

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-PERMANENT HIGH

Among oral anabolics methyltestosterone is strictly dominated — it has the worst hepatotoxicity profile of any clinically used 17αAA, weaker anabolic effect than oxandrolone/oxymetholone/methandrostenolone, and aromatizes to a methylestradiol that is itself harder for the liver to clear. Anyone wanting oral androgen has better tools (oxandrolone for mild, methandrostenolone for mass with cycled liver hits); anyone wanting testosterone has injectable T-enanthate/cypionate at 1/100th the hepatic load. Verdict would only change if a novel hepatoprotective derivative emerged — currently none exists.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-PERMANENT

    No coherent use case. Brain-priority profile explicitly avoids HPG-axis suppressors at age 20 (per profile: "❌ HPG-axis suppressors (anabolic peptides at 20)"). Hepatotoxicity profile is incompatible with all V4/V5 stack components. Aesthetic/anabolic goals are explicitly downstream priorities. Even if hypertrophy were a goal, oxandrolone or injectable T would dominate.

  • 30-50, executive maintenance
    SKIP-PERMANENT

    Modern TRT (transdermal or injectable) handles low-T cleanly. Recreational use risks dominate any benefit.

  • 50+, mild cognitive decline / sarcopenia
    SKIP-PERMANENT

    TRT-indicated population uses transdermal/injectable T; oral T-undecanoate (Jatenzo) where oral preferred. Methyltestosterone's hepatotoxicity is especially poor fit for an aging liver with reduced reserve.

  • Anxiety-prone
    SKIP-PERMANENT

    Mood/aggression effects of supraphysiologic androgen + irritability profile = bad combination.

  • High athletic load, tested status
    SKIP-PERMANENT

    WADA-banned class S1 exogenous androgen. Anabolic effect inferior to oxandrolone/methandrostenolone with much worse hepatic risk. Modern doping protocols don't use it.

  • DylanHigh athletic load, untested status (Dylan's case)
    SKIP-PERMANENT

    Among oral anabolics, methyltestosterone is strictly dominated. Among any anabolic strategy, injectable testosterone esters dominate at fraction of hepatic risk. No use case.

  • Sleep-disordered
    SKIP-PERMANENT

    Polycythemia + sleep apnea exacerbation risk + mood disruption.

  • Recovery-focused (post-injury, post-illness)
    SKIP-PERMANENT

    Hepatic load on a recovering body is wrong direction. Oxandrolone has a niche (burn-recovery FDA approval); methyltestosterone does not.

  • Strength/anabolic-focused
    SKIP-PERMANENT

    Inferior to methandrostenolone for mass, inferior to oxandrolone for cutting, inferior to injectable T for foundation. Dominated on every anabolic axis. Universal verdict: Methyltestosterone is dominated by other AAS for every legitimate use case. There is no preference profile under which methyltestosterone wins.

▸ Subjective experience (deep)

Onset: Detectable androgenic effects (libido bump, mild aggression, increased fluid retention) within 24-72 hours at typical bodybuilding dose (20-30 mg/day). Buccal/sublingual formulations produce a sharper acute peak.

Peak effect: 2-4 weeks for muscle-building effect; week 1-2 for water retention, BP elevation, mood shift.

Plateau: As with all AAS, gains plateau at 4-6 weeks at fixed dose. Discontinuation triggers HPG-suppression-driven libido/mood crash and rapid loss of fluid-mediated mass.

Taper: No real taper — discontinuation is abrupt, with HPG axis recovery beginning over weeks-to-months. PCT (clomiphene/enclomiphene/HCG) standard practice.

Characteristic effects vs other oral AAS:

  • More aggressive water retention than oxandrolone (which doesn't aromatize)
  • More gynecomastia risk than fluoxymesterone (which is non-aromatizing)
  • Worse LFT impact per mg than methandrostenolone or oxandrolone
  • Inferior LBM gain vs methandrostenolone at equipotent hepatic load
  • More mood/aggression effects per anabolic effect than oxandrolone

Honest variability: Substantial. CYP-mediated clearance variability + AR sensitivity polymorphism (CAG repeat length) drive 2-3× variance in subjective response. Liver injury susceptibility also varies — some users tolerate 4-6 week courses with mild LFT bump; others develop cholestasis at 2-3 weeks.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Anabolic effect plateaus at 4-6 weeks at fixed dose. Receptor downregulation modest. Liver toxicity is cumulative — cycling does not "reset" the hepatic burden; each cycle adds incremental hepatocellular stress.
  • Recommended cycle: Don't. If used despite recommendation, 4-6 weeks max with hepatoprotection (NAC 1.2-2.4 g, TUDCA 500-1000 mg) and quarterly LFT monitoring. But note — this is harm-reduction framing, not endorsement.
  • Reset protocol: PCT (clomiphene 25-50 mg/day or enclomiphene 12.5-25 mg/day for 4-6 weeks) to restart endogenous T production. LFTs typically normalize within 8-12 weeks of discontinuation. Peliosis lesions may persist or progress independently.
▸ Stacking deep dive

Synergistic with

  • No legitimate synergy in a 2026 protocol context. Historical bodybuilding stacks combined methyltestosterone with non-17αAA injectables (testosterone enanthate, nandrolone) to "spare" the liver — but the principle is to use less methyltestosterone, not stack it.

Avoid stacking with

  • Other 17α-alkylated AAS (oxandrolone, stanozolol, methandrostenolone, oxymetholone, fluoxymesterone, danazol) — additive hepatotoxicity. Stacking two oral 17αAA is one of the most hepatotoxic things a recreational AAS user can do.
  • Alcohol — dramatically additive hepatic load.
  • Acetaminophen/paracetamol at therapeutic dose — additive hepatotoxicity.
  • Statins — additive lipid disruption + hepatic load.
  • NSAIDs (chronic) — renal + hepatic compounding.
  • Modafinil / adrafinil / other prodrugs with hepatic processing — additive load.
  • Hormonal contraceptives, HRT — additive estrogenic effect + hepatic load.
  • Nephrotoxic compounds (high-dose creatine combined with dehydration in MMA cut, e.g.) — synergistic kidney stress in already androgen-strained kidneys.

Neutral / safe co-administration

  • AI (anastrozole, letrozole) — historically used to mitigate aromatization; mechanically logical but doesn't address hepatotoxicity (the dominant problem).
  • Dylan's V4 supplements — mechanistically neutral, but the hepatic load of methyltestosterone would compound with NAC's hepatoprotective load (which would be a band-aid, not a fix).
▸ Drug interactions deep dive
  • Warfarin / anticoagulants — methyltestosterone potentiates warfarin effect (↑INR), risk of hemorrhage. Documented interaction.
  • Hormonal contraceptives, HRT — competing hormonal pathways; unpredictable effects.
  • Insulin / oral hypoglycemics — AAS improve insulin sensitivity, may require dose reduction in diabetics.
  • CYP3A4 substrates — minor inhibition reported but clinically modest.
  • Hepatotoxic drugs (statins, isoniazid, methotrexate, valproate, acetaminophen, kava) — additive.
  • Levothyroxine — possible TBG-mediated alteration in thyroid status assessment.
▸ Pharmacogenomics
  • AR CAG repeat polymorphism — shorter CAG repeats = higher AR transcriptional activity; users with shorter repeats may be more responsive to androgenic effects (and side effects) at lower dose. CAG ~21 average; range 9-37.
  • CYP3A4/3A5 polymorphism — CYP3A5 expressers (~10% of Caucasians) clear methyltestosterone modestly faster. Effect minor.
  • UGT2B17 polymorphism — affects glucuronidation pathways; deletion carriers (~67% of East Asians) clear native T differently but methyltestosterone bypasses this anyway.
  • HLA-B alleles — unspecified subset may predispose to drug-induced liver injury (DILI). No specific allele identified for methyltestosterone but the class effect is established.
  • For Dylan: 23andMe results pending June 2026. Even with favorable polymorphisms, the catastrophic hepatic profile is a structural class effect, not a pharmacogenomic issue. Genetics cannot rescue this molecule.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Rare US Rx (Methitest, Testred, Android-25) Specialty pharmacy via endocrinologist $40-100/month High (where prescribable) Almost never prescribed in 2026. Replaced clinically by transdermal T (AndroGel, Testim) and injectable T-enanthate/cypionate. Some hospice/oncology cachexia use cases remain.
Compounding pharmacy US/Canada compounding Variable Medium Available on script but rarely indicated.
Gray-market AAS vendor International underground labs (UGLs) $30-60 per 100 tabs at 5-25 mg Low — variable purity, mislabeling common Active 2010s-2020s recreational bodybuilding supply. Not a clean sourcing path.
Indian pharmacy Limited Variable Low Indian pharmaceutical manufacturers do produce methyltestosterone for veterinary + niche human markets but distribution to US end-users is unreliable.
Veterinary Some equine markets historically N/A N/A Mostly decommissioned in modern veterinary use.

Bottom line on sourcing: Methyltestosterone is essentially a historical molecule in 2026. Modern androgen replacement uses injectable testosterone esters, transdermal T, or oral T-undecanoate (Jatenzo / Tlando — non-17αAA, no significant hepatotoxicity). Modern bodybuilding uses methandrostenolone (Dianabol), oxandrolone (Anavar), or oxymetholone (Anadrol) for oral AAS use cases. There is no rational sourcing path for methyltestosterone in 2026.

▸ Biomarkers to track (deep)

If used despite the universal SKIP recommendation:

Baseline (before starting)

  • Liver: ALT, AST, GGT, alkaline phosphatase, total + direct bilirubin, albumin, PT/INR
  • Hepatitis serology: HBV, HCV
  • Lipids: Total cholesterol, LDL-C, HDL-C, ApoB, triglycerides, Lp(a)
  • Hormonal: Total testosterone, free testosterone, SHBG, estradiol (sensitive assay), LH, FSH, prolactin
  • CBC: Hematocrit, hemoglobin, RBC, WBC, platelets
  • Renal: Creatinine, eGFR, cystatin C, BUN
  • Cardiac: Resting BP, ECG; consider echocardiogram if extended use planned
  • Hepatic imaging: Baseline abdominal US for liver/biliary architecture

During use

  • Week 2: full LFT panel — stop drug if ALT/AST >3× ULN, bilirubin >2× ULN, or symptoms (jaundice, RUQ pain, pruritus, dark urine)
  • Week 4: full LFT, lipid panel, CBC — monitor cholestatic markers (bilirubin, GGT, AlkPhos), HDL-C nadir, hematocrit trajectory
  • Week 6: full LFT, lipid, hormonal panel, BP — confirm trajectory, assess HPG suppression
  • Monthly thereafter: full LFT + CBC + BP
  • Quarterly: lipid + hormonal + abdominal US (peliosis surveillance)

Post-cycle

  • Weeks 4-8 post: LFT recheck + hormonal panel — confirm liver normalization and HPG recovery
  • Months 3-6 post: hormonal panel — may require PCT (clomiphene/enclomiphene/HCG) if endogenous T not recovering
  • Annual abdominal imaging for users with extended exposure
▸ Controversies / open debates Live debate

1. "Low-dose methyltestosterone (5-10 mg/day) is safe for andropause"

  • Historical claim: Pre-injectable-T-era endocrinology used 5-25 mg/day MeT for androgen replacement.
  • Modern reality: Even at low dose, chronic 17αAA exposure produces measurable LFT abnormalities and HDL suppression vs transdermal/injectable T which produce neither. Modern endocrinology (Endocrine Society 2018 guidelines, AUA 2023 update) does not recommend methyltestosterone for any indication when injectable or transdermal alternatives exist.

2. "It's the original — must have a use case"

  • Argument: Methyltestosterone has been studied for 90 years; the safety profile is extremely well-characterized.
  • Counter: The well-characterization of the safety profile is itself the argument against use. We know precisely how bad it is. Other AAS that have emerged (oxandrolone 1964, methandrostenolone 1958, stanozolol 1962) provide better anabolic-to-hepatotoxic ratios.

3. "Buccal/sublingual delivery bypasses first-pass and reduces liver toxicity"

  • Mechanism: Buccal MeT (absorbed through oral mucosa) avoids portal circulation, theoretically reducing hepatic exposure.
  • Reality: Reduces but does not eliminate hepatic toxicity, because (a) drug eventually circulates through liver for metabolism regardless of absorption route, and (b) buccal formulations produce sharp peaks that may worsen lipid effects despite lower mean hepatic load. Marketed buccal product Striant (testosterone — not methyl) was the modern attempt at this delivery; methyl versions never reached significant market share.

4. "Methyltestosterone for women's libido"

  • Historical use: Estrogen + low-dose methyltestosterone (Estratest, withdrawn) for postmenopausal female sexual dysfunction.
  • Modern reality: Withdrawn from most markets. Replaced by transdermal testosterone (off-label, unapproved in US for women but used in UK/Australia at 1/10th male dose) or DHEA. MeT's virilization risk and hepatotoxicity make it unsuitable for chronic female use.

5. "Necessary in cachexia / wasting syndromes"

  • Argument: Some hospice / HIV-wasting / oncology cachexia indications have used methyltestosterone historically.
  • Modern reality: Oxandrolone (Oxandrin) has FDA approval for promoting weight gain after extensive surgery, chronic infection, severe trauma, and burn injury. Megestrol acetate, mirtazapine, and (selectively) cannabinoids are first-line for appetite stimulation. Methyltestosterone is no longer first-choice for any cachexia indication.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-PERMANENT / HIGH CONFIDENCE / MEDIUM-priority research pass. Hepatotoxicity profile of 17α-alkylated androgens, with methyltestosterone as the prototype, makes this molecule strictly dominated by every alternative. No anabolic use case wins for methyltestosterone over oxandrolone (cutting), methandrostenolone (bulking), or injectable T-enanthate (foundation). No replacement use case wins over transdermal T, injectable T, or oral T-undecanoate. The molecule is historical. Verdict applies universally across user profiles. No realistic conditions under which verdict would flip.
▸ Open questions / gaps Open
  1. Why did methyltestosterone persist in some 1990s-2000s formulations (Estratest, certain compounding pharmacy products) given its dominated profile? Answer is largely commercial inertia + niche prescriber preference + cheap manufacturing — not clinical merit.
  2. Is there an HLA-B or other DILI-predictive biomarker specific to methyltestosterone vs other 17αAA? Unstudied. Class effect well-established, individual susceptibility prediction not commercially relevant.
  3. What would change the verdict? Nothing realistic. A novel hepatoprotective derivative would not be methyltestosterone (it would be a new molecule with a new name). Methyltestosterone's structure is fixed — and the structural feature that makes it hepatotoxic is the same feature that makes it orally bioavailable.
▸ Sources (full, with our context)
Back to compact view